Details - Pidar

Dataset ID: 11

Back to List

Study Design Background	To synthesis and evaluation of a PSMA-617-targeted dual NIRF/PDTprobe conceived using IRDye700DX as photosensitizer and FGS NIR dye.
Study Description	probe conceived using IRDye700DX as photosensitizer and FGS NIR dye
Study Type	preclinical
Study Subtype	in vivo/ex vivo

Paper Linked	yes
Paper Title	A Novel PSMA-Targeted Probe for NIRF-Guided Surgery andPhotodynamic Therapy: Synthesis and Preclinical Validation
Paper Authors	Capozza, Martina; Stefania, Rachele; Dinatale, Valentina; Bitonto, Valeria; Conti, Laura; Grange, Cristina; Skovronova, Renata; Terreno, Enzo
Affiliation	Molecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy ; Molecular Biotechnology Center, Department of Medical Science, University of Torino, 10126 Torino, Italy; Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy
Paper Journal	IJMS
Paper Year	2022
Paper Doi	https://doi.org/10.3390/ijms232112878
Open Access	yes
Updated Year	2023

Multi Modality Images	yes
Imaging Modality	MRI-OI
Imaging Sub Modality	T2w and fluorescent imaging (filter pair: 640/720 nm)
Radiation	no
Imaging Coverage	body
Imaging Target	PSMA

Institution	UniTO
Pi	Enzo Terreno
Country Of Institution	Italy
Imaging Facility	Laboratory of molecular imaging for small animal
Euro Bio Imaging Node	MMMI
Country Of Imaging Facility	Italy
Contact Person	martina.capozza@unito.it

Number Of Groups	5
Types Of Groups	1nmol PSMA+ inj biod; 5nmol PSMA+ inj biod; 5 nmol PSMA- biod; PSMA+ PDT treated; PSMA+ Ctrl
Overall Sample Size	25
Disease Model	cancer
Organ Or Tissue	prostate
Sample Size For Each Group	5, 5, 5, 5, 5
Power Calculation	none
Randomization	mice were randomly divided into treted and control group
Blinding	no
Outcome Measures	fluorescent uptake, tumor volume
Statistical Methods	anova and t-test
Species	Mice
Strain	athymic nude
Immune Status	immunodeficient
Sex	male
Age	5 weeks
Age At Start Experiment	6 weeks
Age At Scanning Experiment S	older than 8 weeks
Weight	20g
Weight At Start Experiment	20
Weight At End Experiment	20
Source Of Animals	envigo
Registry Number Of Animal Authorization	229/2016

Pharmacological Drug	IRDye700DX-PSMA
Company	unito
Formulation	PBS
Drug Dose	1-5 nmol/mice
Frequency Of Administration	once
Vehicle Or Carrier Solution Formulation	PBS
Blood Sampling	no
Pathogen Infection Intervention And Control	no
Analgesic Plan To Relieve Pain Suffering And Distress	no
Anesthesia Type	intramuscolar
Duration	45
Anesthesia Drugs	Zoletil/Rompun
Anesthesia Dose	20 mg/kg tiletamine/zolazepam (Zoletil 100; Virbac, Milan, Italy) and 5 mg/kg xylazine (Rompun; Bayer, Milan, Italy).
Euthanasia	yes
Method	cervival dislocation
Histology	yes
Tissues Collected Post Euthanasia	tumor
Timing Of Collection	different time points
Histological Procedure	optical cutting temperature (OCT) compound
Name Of Reagent S	anti-CD68, anti PSMA, anti CD31,
Frequency Of Imaging	2 times/week MRI
Timing Of Imaging	three weeks after inoculation
Overall Scan Length	20 min
Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule	no
Cell Line	PC3-PIP and PC3-FLU
Provenance	THE JOHNS HOPKINS UNIVERSITY
Modified Cell Line	yes
Type Of Genetic Modification	plasmid
Gene Modified	PSMA
Cell Injection Route	subcutaneous
Number Of Cells	2x10^6
Housing Room	SPF and not SPF
Dietary Intervention	diet for OI

Instrument Vendor	Bruker for MRI and Perkin Elmer for OI
Instrument Type	7 T Bruker Pharmascan, IVIS spectrum
Instrument Specifics	7T
Raw Data	yes

Image Scale	average radiance efficiency for OI
Format Compression	raw
Dimensions	2D
Overall Number Of Images	32 x MRI; 7 x OI
Field Of View	30x30 for MRI; D for Ivis
Dimension Extents	128x128
Size Description	30x30x2 mm
Image Processing Methods	default

Analysis Result Type	numerical
Data Used For Analysis	ROI
Analysis Method And Details	manual
File Format Of Result File Csv Json Txt Xlsx	xlsx
Status	complete

Back to List